"This will be a defining year for AI," Zuckerberg said in a Facebook post. "Over the coming years, it will drive our core products and business."
CEO Mark Zuckerberg announced that Meta Platforms (META.O) plans to invest as much as $65bn in 2025 to expand its artificial intelligence (AI) infrastructure. This substantial investment aims to bolster Meta’s AI capabilities and strengthen its competitive position against rivals such as OpenAI and Google in the rapidly evolving AI market.
In a meeting with Meta employees on Thursday, Mr. Zuckerberg also doubled down on recent changes to the company’s online speech policies and ending its diversity initiatives.
Meta Platforms plans to spend between $60 billion and $65 billion this year to build out AI infrastructure, CEO Mark Zuckerberg said ... Group 9984.T and Oracle ORCL.N will form a venture ...
Meta Platforms plans to spend between $60 billion and $65 billion this year to build out AI infrastructure, CEO Mark Zuckerberg said today, joining a wave of Big Tech firms unveiling hefty investments to capitalise on the technology.
US stocks gained steam on Thursday afternoon as investors digested megacap tech earnings and waited for Apple (AAPL) results for more clues on prospects for Big Tech. Right ahead of the closing bell,
Key Takeaways Microsoft, Meta, and IBM all highlighted healthy growth in their AI businesses in the last three months of 2024.Microsoft and Meta, which cumulatively expect to invest nearly $150 billion in infrastructure in their respective 2025 fiscal years,
Meta CEO Mark Zuckerberg teased a "return to OG Facebook" as part of his key goals for 2025 in Wednesday's Q4 earnings call with investors. While the
US stocks edged up on Thursday, with the S&P 500 eyeing a small comeback as investors digested megacap tech earnings and waited for Apple (AAPL) results for more clues on prospects for Big Tech. After the Federal Reserve stood pat on interest rates as expected,
US stocks struggled to make headway on Thursday as investors digested megacap tech earnings and waited for Apple (AAPL) results for more clues on prospects for Big Tech. After the Federal Reserve stood pat on interest rates as expected,
This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy point.
Rating for Harmony Biosciences stock jumped into a new percentile Thursday, with an increase from 70 to 83. This proprietary rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.